MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Seattle Genetics Company Profile (NASDAQ:SGEN)

Consensus Ratings for Seattle Genetics (NASDAQ:SGEN) (?)
Ratings Breakdown: 1 Sell Rating(s), 5 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $47.54 (22.62% upside)

Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Needham & Company LLCReiterated RatingBuy$60.00 -> $72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016HC WainwrightReiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Cantor FitzgeraldReiterated RatingBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016SunTrustInitiated CoverageNeutral$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016OppenheimerReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Leerink SwannLower Price TargetOutperform$56.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016BarclaysLower Price TargetOverweight$51.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Piper JaffrayLower Price TargetNeutral$44.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016JPMorgan Chase & Co.Lower Price TargetNeutral$45.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2015Goldman SachsInitiated CoverageSell$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/14/2015RBC CapitalLower Price TargetOutperform$56.00 -> $54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2015William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015Bank of AmericaReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2015Jefferies GroupSet Price TargetBuy$53.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Seattle Genetics (NASDAQ:SGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20161($0.29)($0.29)($0.29)
Q3 20161($0.35)($0.35)($0.35)
Q4 20161($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)
Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Seattle Genetics (NASDAQ:SGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Seattle Genetics (NASDAQ:SGEN)
DateHeadline
06/29/16 09:07 AMTop Stock Pick for Quarter: Seattle Genetics, Inc. (NASDAQ:SGEN) - Engelwood Daily
06/29/16 09:07 AMHow Analysts Feel About Seattle Genetics, Inc. (NASDAQ:SGEN)? - Engelwood Daily
06/28/16 06:16 PMSeattle Genetics Larger Than S&P 500 Component Murphy Oil Corp
06/25/16 10:03 AMRedmile Group LLC Decreased Stake in Seattle Genetics INC (NASDAQ:SGEN) by $14.08 Million as Shares Declined - Press Telegraph
06/25/16 10:03 AMStrong Sell Calls Recommendations For Seattle Genetics, Inc. (NASDAQ:SGEN) At 0 - Investor Newswire
06/24/16 06:26 PM10 Companies with Awesome Training and Development Programs
06/24/16 08:55 AMPrice Target Update on Seattle Genetics (NASDAQ:SGEN) - Trade Calls
06/23/16 07:01 PMSeattle Genetics (NASDAQ:SGEN) Analyst Rating Consensus - TheFounders Daily
06/23/16 07:01 PMRecently Issued Stock Ratings For Seattle Genetics, Inc. (NASDAQ:SGEN) - Fiscal Standard
06/21/16 10:36 AMSeattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : June 21, 2016 -
06/20/16 07:53 AMSeattle Genetics, Inc. (NASDAQ:SGEN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 07:38 AMSeattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : June 20, 2016 -
06/17/16 06:05 PMStrong Buy Calls Count For Seattle Genetics, Inc. (NASDAQ:SGEN) At 5 - Investor Newswire
06/16/16 10:42 AMWhich way Seattle Genetics, Inc. (NASDAQ:SGEN) earnings may go - iStreetWire
06/14/16 11:08 AMFriday Stock's Price Swings: Thermo Fisher Scientific Inc (NYSE:TMO) , Seattle Genetics, Inc. (NASDAQ:SGEN) - Street Updates
06/12/16 09:01 AMStock is down at $40.38 (SGEN) Seattle Genetics Highlights Vadastuximab…
06/11/16 01:30 AMSeattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association - [PR Newswire] - 33A is an investigational antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. CD33 is expressed on leukemic blasts in nearly all AML patients with expression generally consistent regardless of age, cytogenetic abnormalities or underlying mutations. Based on data from the ongoing phase 1 clinical trial, a phase 3 clinical trial, called CASCADE, was recently initiated evaluating 33A in combination with HMAs in previously untreated AML patients not candidates for intensive induction chemotherapy.
06/10/16 05:41 PMSeattle Genetics Has Been Heating Up: Time to Buy? -
06/09/16 06:51 PMSeattle Genetics, Inc. (NASDAQ:SGEN) Fundamental Star Rating Report - CML News
06/06/16 06:28 PMSEATTLE GENETICS INC. (NASDAQ:SGEN) Financial Condition Compared to S&P 500 - CML News
06/06/16 10:17 AMSeattle Genetics (SGEN), Astellas Pharma Will Present ASG-15ME, ASG-22ME Data at ASCO - StreetInsider.com
06/04/16 06:24 PMEarnings Analysis to see: Sally Beauty Holdings Inc. (NYSE:SBH), Seattle Genetics, Inc. (NASDAQ:SGEN) - Beacon Chronicle
06/04/16 09:20 AMStock To Watch: Seattle Genetics (SGEN) In Perilous Reversal - TheStreet.com
06/03/16 06:59 PMStock Review and Earnings Check on Seattle Genetics, Inc. (NASDAQ:SGEN) - HNN
06/03/16 06:59 PMPrice Target by Analysts: Seattle Genetics, Inc. (NASDAQ:SGEN), CMS Energy Corp. (NYSE:CMS) - Beacon Chronicle
06/03/16 09:20 AMImmunoGen (NASDAQ:IMGN) Surged 7.48%: Seattle Genetics (NASDAQ:SGEN), Stemline Therapeutics, Inc ... - KC Register
06/03/16 08:06 AMHere’s What Else Is Happening Now for Ionis -
06/02/16 09:30 AMSeattle Genetics (SGEN) Is Strong On High Volume Today - TheStreet.com - TheStreet.comSeattle Genetics (SGEN) Is Strong On High Volume TodayTheStreet.comSEATTLE GENETICS INC has improved earnings per share by 11.8% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the ...
05/31/16 09:46 AMNoticeable Insider Selling: Seattle Genetics, Inc. (NASDAQ:SGEN) - The Point Review - The Point ReviewNoticeable Insider Selling: Seattle Genetics, Inc. (NASDAQ:SGEN)The Point ReviewSeattle Genetics, Inc. (NASDAQ:SGEN) insiders have most recently took part in a trading activity. On 5/24/2016 Siegall Clay B, President and CEO sold 1,700 shares having total worth of $68,000 at the price of $40.00 per share, following the transaction ...Seattle Genetics (NASDAQ:SGEN) rose 1.64%: Verizon Communication (NYSE:VZ), Alphabet Inc (NASDAQ:GOOG ...Benchmark MonitorSeattle Genetics Incorporated (NASDAQ:SGEN) Short Interest Increased By 1.74%Franklin IndependentAfter Last Week What Do Analysts Think Of Seattle Genetics, Inc. (NASDAQ:SGEN)Share Trading Newsall 5 news articles »
05/27/16 06:47 PMHere’s All You Need To Know About Seattle Genetics, Inc.’s (NASDAQ:SGEN) AML Pivotal - Seattle Genetics, Inc. (NASDAQ:SGEN) just kicked off a pivotal phase 3 trial in its lead acute myeloid leukemia candidate. There are very few effective treatment options available at present, and so – especially in newly diagnosed patients – this ...
05/26/16 06:42 PMHere's All You Need To Know About Seattle Genetics, Inc.'s (NASDAQ:SGEN) AML Pivotal - Market Exclusive - Market ExclusiveHere's All You Need To Know About Seattle Genetics, Inc.'s (NASDAQ:SGEN) AML PivotalMarket ExclusiveSeattle Genetics, Inc. (NASDAQ:SGEN) just kicked off a pivotal phase 3 trial in its lead acute myeloid leukemia candidate. There are very few effective treatment options available at present, and so – especially in newly diagnosed patients – this ...Eventide Asset Management LLC Increased Seattle Genetics INC (NASDAQ:SGEN) by $10.16 Million as Shares ...CCH Daily NewsSeattle Genetics Inc /wa (SGEN) Files Form 4 Insider Selling : Clay B Siegall Sells 8400 SharesMarket DigestThe Insider, Clay Siegall Sold 8400 Shares of Seattle Genetics, Inc. (NASDAQ:SGEN)The PostFTSE News -SmallCap Network -Nasdaqall 12 news articles »
05/26/16 02:59 PMSeattle Genetics Starts Trial on Acute Myeloid Leukemia Drug -
05/25/16 11:42 PMPivot Pharmaceuticals (PVOTF) Rips a Page From the Seattle Genetics (SGEN) Playbook - SmallCap Network - Pivot Pharmaceuticals (PVOTF) Rips a Page From the Seattle Genetics (SGEN) PlaybookSmallCap NetworkCongratulations to Seattle Genetics, Inc. (NASDAQ:SGEN), and for that matter, congratulations to SGEN shareholders. The company announced today it had Initiated a phase 3 trial of vadastuximab talirine (SGN-CD33A) for patients with newly diagnosed ...Seattle Genetics, Inc. (NASDAQ:SGEN) Updated Price TargetsFTSE NewsSeattle Genetics Shares Rise Nearly 2%; Starts Phase 3 Trial of Vadastuximab Talirine in Acute Myeloid Leukemia ...Sonoran Weekly ReviewSeattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly ...Business Wire (press release)Finance Dailyall 7 news articles »
05/25/16 03:46 PMSEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vo -
05/25/16 10:04 AMMost Recent Stocks Report: FibroGen, Inc (NASDAQ:FGEN) , Seattle Genetics, Inc. (NASDAQ:SGEN) - Street Updates - Most Recent Stocks Report: FibroGen, Inc (NASDAQ:FGEN) , Seattle Genetics, Inc. (NASDAQ:SGEN)Street UpdatesSeattle Genetics, Inc. (NASDAQ:SGEN) after beginning at $39.78, closed at $39.97 by building up +1.40% in recent trading session. Most recent session's volume of 751.83 thousand shares lower than its average volume of 1.08 million shares. The company ...Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly ...Business Wire (press release)all 2 news articles »
05/25/16 07:02 AM8:02 am Seattle Genetics initiates a phase 3 clinical trial, called CASCADE, evaluating vadastuximab talirine in combination with azacitidine or decitabine in older patients with acute myeloid leukemia -
05/25/16 07:00 AMSeattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) - [Business Wire] - Seattle Genetics, Inc. today announced initiation of a pivotal phase 3 clinical trial, called CASCADE, evaluating vadastuximab talirine in combination with azacitidine or decitabine in older patients with newly diagnosed acute myeloid leukemia .
05/24/16 11:46 PMForm 4 SEATTLE GENETICS INC For: May 20 Filed by: WELCH DANIEL G - 1. These shares represent restricted stock units and will be settled in common stock upon vesting. 2. Restricted stock units shall vest in full on May 19, 2017. 3. The option shall vest in full on May 19, 2017. /s/ Todd Simpson 05/24/2016 ** Signature of ...
05/24/16 06:38 PMHealthcare Stocks In The News: Incyte Corporation (NASDAQ:INCY), Seattle Genetics, Inc. (NASDAQ:SGEN) - NYSE Journal (press release) - NYSE Journal (press release)Healthcare Stocks In The News: Incyte Corporation (NASDAQ:INCY), Seattle Genetics, Inc. (NASDAQ:SGEN)NYSE Journal (press release)Incyte Corporation (NASDAQ:INCY) belongs to Healthcare sector and Biotechnology industry. INCY stock opened its current trade at $77.97 and now is floating in a range of $77.69 to $81.81, trading at $81.41. INCY stock gained 4.84% in total of its share ...and more »
05/23/16 06:32 PMJuly 15th Options Now Available For Seattle Genetics (SGEN) - Nasdaq - NasdaqJuly 15th Options Now Available For Seattle Genetics (SGEN)NasdaqInvestors in Seattle Genetics Inc (Symbol: SGEN) saw new options begin trading today, for the July 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the SGEN options chain for the new July 15th contracts and ...and more »
05/19/16 06:32 PMSeattle Genetics, Inc. (NASDAQ:SGEN) To Report June 2016 Results - Street Register - Seattle Genetics, Inc. (NASDAQ:SGEN) To Report June 2016 ResultsStreet RegisterSeattle Genetics, Inc. (SGEN) added 6.05% to reach at the floor price of $38.02 as the company is set to share its next quarterly earnings on July 28, 2016. SGEN stock trades between $35.6 and $38.35 before the earnings release. Let's take a closer ...
05/19/16 03:13 PMETF’s with exposure to Seattle Genetics, Inc. : May 19, 2016 -
05/18/16 07:13 AMSeattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : May 18, 2016 -
05/17/16 11:27 PMSeattle Genetics, Inc. (NASDAQ:SGEN) Comprehensive Income At $-0.683 - Investor Newswire - Seattle Genetics, Inc. (NASDAQ:SGEN) Comprehensive Income At $-0.683Investor NewswireFor the year ended 2015-12-31, Seattle Genetics, Inc. (NASDAQ:SGEN) costs of goods sold came at $37.44 millions, and for the quarter ended 2015-12-31, it came at $37.44. Cost of goods sold can be stated as the direct costs that are associated with the ...Seattle Genetics, Inc. (NASDAQ:SGEN) topped earnings-per-share estimates 25% of the timeZergwatchAre Analysts Bearish Seattle Genetics, Inc. (NASDAQ:SGEN) After Last Week?Franklin IndependentEventide Asset Management Llc Increased Seattle Genetics Inc (NASDAQ:SGEN) by $10.16 Million as Shares DeclinedThe PostStreet Updates -Wall Street Hints and Newsall 7 news articles »
05/17/16 06:20 PMPrimecap Management Company Increased Seattle Genetics (NASDAQ:SGEN) by $24.75 Million as Shares Declined - CCH Daily News - Primecap Management Company Increased Seattle Genetics (NASDAQ:SGEN) by $24.75 Million as Shares DeclinedCCH Daily NewsPrimecap Management Company increased its stake in Seattle Genetics (NASDAQ:SGEN) by 5.49% based on its latest 2016Q1 regulatory filing with the SEC. Primecap Management Company bought 707,012 shares as the company's stock declined 16.29% ...and more »
05/16/16 06:13 PMMovers inside Traders Limelight: Seattle Genetics, Inc. (NASDAQ:SGEN) , Momenta Pharmaceuticals, Inc. (NASDAQ ... - Street Updates - Movers inside Traders Limelight: Seattle Genetics, Inc. (NASDAQ:SGEN) , Momenta Pharmaceuticals, Inc. (NASDAQ ...Street UpdatesOn 5/13/2016, shares of Seattle Genetics, Inc. (NASDAQ:SGEN) fell +0.00% in trading session and finally closed at $32.95. The company most recent volume stood at 664.98 thousand shares as compared to its average volume of 1.1 million shares. Over the ...Eventide Asset Management Llc Increased Seattle Genetics Inc (NASDAQ:SGEN) by $10.16 Million as Shares DeclinedThe Postall 3 news articles »
05/13/16 03:43 PMSEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers -
05/12/16 06:56 PMTraded Price Fluctuations to Observe: Seattle Genetics, Inc. (NASDAQ:SGEN) , Sangamo BioSciences, Inc. (NASDAQ ... - Street Updates - Traded Price Fluctuations to Observe: Seattle Genetics, Inc. (NASDAQ:SGEN) , Sangamo BioSciences, Inc. (NASDAQ ...Street UpdatesOn 5/11/2016, Seattle Genetics, Inc. (NASDAQ:SGEN) ended trading session lower at $33.70 with -0.59%. The company traded a volume of 751.17 thousand shares as comparison to average volume of 1.11 million shares. During the 52 –week period, the ...and more »
05/10/16 06:52 PMEarnings per Share Report: Seattle Genetics (NASDAQ:SGEN) - News Oracle - Earnings per Share Report: Seattle Genetics (NASDAQ:SGEN)News OracleLast Trade: The Company rose 1.76% and finished at $34.20. The daily volume was measured at 811,231.00 shares. The 52-week high of the share price is $52.33 the 52-week low is $26.02. The company has a market cap of $4.85 Billion. Its latest closing ...and more »
05/10/16 06:52 PMSeattle Genetics, Inc. (NASDAQ:SGEN) Comprehensive Income At $-0.683 For Period Ended 2015-12-31 - Investor Newswire - Seattle Genetics, Inc. (NASDAQ:SGEN) Comprehensive Income At $-0.683 For Period Ended 2015-12-31Investor NewswireFor the year ended 2015-12-31, Seattle Genetics, Inc. (NASDAQ:SGEN) spent $37.44 millions as the costs of goods sold, which stood at $37.44 millions for the quarter ended 2015-12-31. Cost of goods sold are the direct costs related to the production of ...
About Seattle Genetics

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Company's pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics' sugar-engineered antibody (SEA) technology.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SGEN
  • CUSIP: 81257810
Key Metrics:
  • Previous Close: $38.77
  • 50 Day Moving Average: $38.83
  • 200 Day Moving Average: $36.46
  • P/E Ratio: N/A
  • P/E Growth: -2.04
  • Market Cap: $5.47B
  • Current Quarter EPS Consensus Estimate: $-1.09 EPS
Additional Links:
Seattle Genetics (NASDAQ:SGEN) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha